Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 10/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | ABL2 | P42684 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24458674 | 0.86 | BTK (0.47) | EGFRKDR | |
| SCHEMBL24458698 | 0.86 | SRC (0.47) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL29552410 | 0.86 | SRC (0.47) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL24459022 | 0.84 | SRC (0.49) | SRCEGFRABL1ABL2RET | |
| SCHEMBL24459026 | 0.83 | SRC (0.50) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL24458936 | 0.78 | FGFR2 (0.47) | EGFRKDR | |
| SCHEMBL24458346 | 0.78 | SRC (0.51) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL29552579 | 0.78 | SRC (0.51) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL24459024 | 0.77 | BTK (0.51) | SRCEGFRABL1RETKDR | |
| SCHEMBL24458388 | 0.76 | BTK (0.55) | SRCEGFRABL1ABL2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022109551-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |